randomized_controlled_trial · 2024
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
le Roux CW, Steen O, Lucas KJ, et al. · The Lancet Diabetes & Endocrinology
moderateDOI · 10.1016/s2213-8587(23)00356-xPMID · 38330987Verified
Plain-English summary
Survodutide produced dose-dependent weight loss, with gastrointestinal side effects particularly during dose escalation. It remained investigational.
Population
Adults with a body mass index of at least 27 kg/m² without diabetes
Sample size
387
Intervention
Once-weekly survodutide across multiple maintenance doses versus placebo for 46 weeks
Outcomes measured
Percentage change in body weight|Dose response|Weight-loss thresholds|Safety and tolerability
Key findings
All tested doses reduced body weight relative to placebo in a dose-dependent manner; gastrointestinal disorders were the most frequent adverse events.
Funding & disclosures
Funded by Boehringer Ingelheim; authors included employees and investigators with relevant industry relationships.
Limitations
The study was phase 2 and not powered for long-term clinical outcomes or rare safety events. Treatment discontinuation and gastrointestinal tolerability affect interpretation.Risk of bias
Low to moderate — randomized and double-blind, with commercial sponsorship and sponsor involvement.Citation
le Roux CW, Steen O, Lucas KJ, et al. (2024). Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(23)00356-x
Linked peptides in the PeptiBrief database